We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+15.9%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.81B
AUM Growth
+$276M
Cap. Flow
-$211M
Cap. Flow %
-4.39%
Top 10 Hldgs %
49.94%
Holding
159
New
17
Increased
40
Reduced
75
Closed
11

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$87M
2
RVMD icon
Revolution Medicines
RVMD
+$38.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.8M
4
AKRO
Akero Therapeutics
AKRO
+$19.6M
5
IMCR icon
Immunocore
IMCR
+$12.1M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$93.6M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$78.5M
3
BPMC
Blueprint Medicines
BPMC
+$36.5M
4
MRNA icon
Moderna
MRNA
+$34.3M
5
SYK icon
Stryker
SYK
+$32.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Technology 0.03%
3 Consumer Discretionary 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRVA icon
51
Privia Health
PRVA
$3.33B
$16.6M 0.34%
666,177
+35,480
+6% +$764K
PRCT icon
52
Procept Biorobotics
PRCT
$1.08B
$16.5M 0.34%
463,404
-25,874
-5% -$1.18M
ANNX icon
53
Annexon
ANNX
$957M
$15.7M 0.33%
5,157,290
– –
EHC icon
54
Encompass Health
EHC
$11.1B
$15.6M 0.32%
122,958
-8,783
-7% -$1.05M
NTRA icon
55
Natera
NTRA
$38.3B
$14.8M 0.31%
91,818
-55,673
-38% -$8.81M
MASI
56
DELISTED
Masimo
MASI
$14.3M 0.3%
96,968
+7,295
+8% +$1.1M
JNJ icon
57
Johnson & Johnson
JNJ
$610B
$13.9M 0.29%
74,807
+6,596
+10% +$1.13M
EXAS
58
DELISTED
Exact Sciences
EXAS
$13.8M 0.29%
252,701
-31,500
-11% -$1.57M
TMDX icon
59
Transmedics
TMDX
$2.5B
$13.1M 0.27%
116,968
-13,549
-10% -$1.59M
ONC
60
BeOne Medicines Ltd
ONC
$32.8B
$11.5M 0.24%
33,797
-4,901
-13% -$1.49M
CNC icon
61
Centene
CNC
$32.9B
$10.1M 0.21%
281,949
+142,639
+102% +$4.31M
IQV icon
62
IQVIA
IQV
$34B
$10M 0.21%
52,898
+19,198
+57% +$3.49M
GPCR icon
63
Structure Therapeutics
GPCR
$3.44B
$8.84M 0.18%
315,857
-32,670
-9% -$651K
TEVA icon
64
Teva Pharmaceuticals
TEVA
$37.4B
$8.57M 0.18%
424,056
+2,555
+0.6% +$44.9K
REGN icon
65
Regeneron Pharmaceuticals
REGN
$70.6B
$8.47M 0.18%
15,057
-11,687
-44% -$6.61M
CDNA icon
66
CareDx
CDNA
$2B
$8.33M 0.17%
572,956
-179,415
-24% -$2.56M
THC icon
67
Tenet Healthcare
THC
$16.8B
$8.2M 0.17%
+40,372
New +$7.16M
PHR icon
68
Phreesia
PHR
$650M
$7.36M 0.15%
313,057
-18,959
-6% -$516K
AXSM icon
69
Axsome Therapeutics
AXSM
$11.9B
$6.36M 0.13%
52,335
-3,918
-7% -$441K
DGX icon
70
Quest Diagnostics
DGX
$23.3B
$6.29M 0.13%
33,015
-15,552
-32% -$2.76M
BTSG icon
71
BrightSpring Health Services
BTSG
$14.2B
$5.63M 0.12%
190,524
-1,182
-0.6% -$27.5K
OMDA
72
Omada Health Inc
OMDA
$1.4B
$5.57M 0.12%
251,791
+1,791
+0.7% +$36.7K
GILD icon
73
Gilead Sciences
GILD
$166B
$5.54M 0.12%
49,893
-1,523
-3% -$173K
BMRN icon
74
BioMarin Pharmaceuticals
BMRN
$11.5B
$5.47M 0.11%
101,033
-50,412
-33% -$2.88M
ASND icon
75
Ascendis Pharma A/S
ASND
$17.3B
$4.95M 0.1%
24,903
-3,752
-13% -$700K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2025 Portfolio in Review

As of Q3 2025, Bellevue Group held 159 positions worth $4.81B, up 6.1% from $4.54B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group withdrew a net $211M in Q3 2025, closing 11 positions and reducing 75 holdings. Its most notable exit was Blueprint Medicines, an estimated $36.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Avidity Biosciences worth $93.8M.

  • Bellevue Group's largest Q3 2025 buy was Avidity Biosciences: 2,152,862 shares worth $93.8M.
  • Bellevue Group added most to Revolution Medicines in Q3 2025, an estimated $38.9M increase.
  • Bellevue Group's biggest Q3 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $93.6M.
  • Bellevue Group fully exited Blueprint Medicines in Q3 2025, selling an estimated $36.5M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.81B portfolio in Q3 2025.
  • Bellevue Group opened 17 new positions and closed 11 in Q3 2025.
  • Bellevue Group's portfolio value rose 6.1% quarter-over-quarter to $4.81B.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.